Effects of simvastatin on serum adiponectin: a meta-analysis of randomized controlled trials

Abstract

BackgroundEffects of simvastatin on serum level of adiponectin, a protein conferring benefits in both cardiovascular and metabolic system, are not fully determined.MethodsA meta-analysis of randomized controlled trials (RCTs) was performed. Studies were identified by searching of Pubmed, Embase, and the Cochrane Library databases. Heterogeneity among the RCTs was determined by Cochrane’s Q test and I2 statistics. Meta-analysis was performed with random-effect model or fixed-effect model according to the heterogeneity. Meta-regression and subgroup analyses were performed to analyze the source of heterogeneity.ResultsTwelve RCTs with 16 comparisons and 1042 patients were included. Overall, serum adiponectin was not significantly affected by simvastatin (WMD: 0.42 μg/mL; 95% CI, -0.66–1.50 μg/mL). However, significant heterogeneity was detected (Cochrane’s Q test: p < 0.01; I2 = 83%). Subsequent meta-regression analyses indicated that treatment duration was a significant determinant of the effects of simvastatin treatment on serum adiponectin (Coefficient 0.04, p = 0.03). Subgroup analyses demonstrated that simvastatin treatment was associated with increased adiponectin in studies with treatment duration of 12 weeks (WMD: 3.65 μg/mL; p < 0.01), but not in studies with treatment duration of ≤ 8 weeks (WMD: -0.20 μg/mL; p = 0.38). The different between the two stratums was significant (p < 0.01).ConclusionsTreatment with simvastatin of 12 weeks may increase the serum level adiponectin in patients at risk for cardiovascular diseases, but not for the short term treatment of ≤ 8 weeks.

Adipokines and Adipose Tissue-Related Metabolites, Nuts and Cardiovascular Disease

“…Adiponectin increases insulin sensitivity [117], an effect also observed after weight loss and the consequent increase in plasma levels [118]. Simvastatin treatment, often observed in patients with CVD, increases adiponectin levels over 12 weeks but not below 8 weeks [119].…”

Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives

“…A meta-analysis of 12 RCTs with 16 comparisons and 1042 patients showed that serum adiponectin was not significantly affected by simvastatin (WMD: 0.42 μg/mL; 95% CI, −0.66 to 1.50 μg/mL) [ 180 ]. In a systematic review and meta-analysis of 43 studies, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18 to 0.95, p = 0.004) [ 181 ].…”

Adiponectin’s roles in lipid and glucose metabolism modulation in fish: Mechanisms and perspectives

“…One is to increase levels of adiponectin, such as injection of adiponectin and increase of adiponectin expression via compounds. The second is to activate AdipoRs, including small molecule and peptide agonist activating AdipoRs or increase levels of AdipoRs metformin and liraglutide and Exenatide, [134][135][136][137][138] and hypolipidemia drugs, such as statin, ezetimibe and fibrate, [139][140][141] have all been shown to increase adiponectin concentrations in the plasma.…”

“…Furthermore, some compounds are used to increase adiponectin expression. PPARγ agonist drugs, such as troglitazone, pioglitazone, rosiglitazone and MK‐0767, 98,130–133 anti‐diabetic drugs, such as dipeptidyl peptidase‐4 inhibitors (DPP4i), α‐Glycosidase inhibitors, metformin and liraglutide and Exenatide, 134–138 and hypolipidemia drugs, such as statin, ezetimibe and fibrate, 139–141 have all been shown to increase adiponectin concentrations in the plasma.…”